التفاصيل البيبلوغرافية
| العنوان: |
Response of NOTCH1-Activated Tracheal Adenoid Cystic Carcinoma to the Gamma Secretase Inhibitor Nirogacestat. |
| المؤلفون: |
Kieran, Rosalind, de Paula, Bruno H. R., Hubank, Michael, Barker, Allanah, Paterson, Anna L., Gilligan, David, Doherty, Gary J. |
| المصدر: |
JCO Precision Oncology; 10/6/2021, Vol. 5, p1579-1583, 5p |
| مصطلحات موضوعية: |
SECRETASE inhibitors, ADENOID cystic carcinoma, PHYSICIANS |
| مستخلص: |
Primary tumors of the trachea are rare, with an incidence of around 2.6 cases per million people per year.[1] Around one third of these are adenoid cystic carcinoma (ACC). Discussion To the best of our knowledge, this case describes the first patient with NOTCH1-driven metastatic ACC successfully treated with the gamma secretase inhibitor nirogacestat, which led to durable disease control in a condition of unmet need, devoid of established systemic treatment options. However, the patient necessarily discontinued therapy during the second treatment cycle owing to (potentially drug-related) liver toxicity and had disease progression 44 days after treatment discontinuation.[4] Nirogacestat (previously, PF-03084014) inhibits NOTCH signaling through a distinct mechanism. [Extracted from the article] |
|
Copyright of JCO Precision Oncology is the property of American Society of Clinical Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
